Meeting of the Advisory Committee on Blood and Tissue Safety and Availability, 49549 [2021-19026]

Download as PDF Federal Register / Vol. 86, No. 169 / Friday, September 3, 2021 / Notices Dated: August 20, 2021. Lauren K. Roth, Acting Principal Associate Commissioner for Policy [FR Doc. 2021–19096 Filed 9–2–21; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the Advisory Committee on Blood and Tissue Safety and Availability Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: The U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) will hold a virtual meeting. The meeting will be open to the public. The committee will discuss and vote on recommendations to improve the supply chain and data infrastructure that supports the blood industry, especially during public health emergencies. This meeting will build upon the presentations and discussions held during the 53rd ACBTSA meeting from August 17–18, 2021. DATES: The meeting will take place virtually on Thursday, September 23, 2021 from approximately 1:00 p.m.–4:00 p.m. Eastern Time (ET). Meeting times are tentative and subject to change. The confirmed times and agenda items for the meeting will be posted on the ACBTSA web page at https:// www.hhs.gov/oidp/advisory-committee/ blood-tissue-safety-availability/ meetings/2021-09-23/ when this information becomes available. FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, Mary E. Switzer Building, 330 C Street SW, Suite L600, Washington, DC 20024. Email: ACBTSA@hhs.gov. SUPPLEMENTARY INFORMATION: ACBTSA is a discretionary Federal advisory committee. ACBTSA The Committee is governed by the provisions of the Federal Advisory Committee Act (FACA), Public Law 92–463, as amended (5 U.S.C. app), which sets forth standards for the formation and use of advisory committees. On the day of the meeting, please go to https:// www.hhs.gov/live/ to view lotter on DSK11XQN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 16:55 Sep 02, 2021 Jkt 253001 the meeting. The public will have an opportunity to present their views to the ACBTSA by submitting a written public comment. Comments should be pertinent to the meeting discussion. Persons who wish to provide written public comment should review instructions at https://www.hhs.gov/ oidp/advisory-committee/blood-tissuesafety-availability/meetings/2021-09-23/ index.html and respond by midnight September 16, 2021, ET. Written public comments will be accessible to the public on the ACBTSA web page prior to the meeting. ACBTSA functions to provide advice to the Secretary through the Assistant Secretary for Health on a range of policy issues to include: (1) Identification of public health issues through surveillance of blood and tissue safety issues with national survey and data tools; (2) identification of public health issues that affect availability of blood, blood products, and tissues; (3) broad public health, ethical, and legal issues related to the safety of blood, blood products, and tissues; (4) the impact of various economic factors (e.g., product cost and supply) on safety and availability of blood, blood products, and tissues; (5) risk communications related to blood transfusion and tissue transplantation; and (6) identification of infectious disease transmission issues for blood, organs, blood stem cells and tissues. The Committee has met regularly since its establishment in 1997. Dated: August 27, 2021. James J. Berger, Designated Federal Officer, Advisory Committee on Blood and Tissue Safety and Availability, Office of Infectious Disease and HIV/AIDS Policy. [FR Doc. 2021–19026 Filed 9–2–21; 8:45 am] BILLING CODE 4150–28–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Federal Licensing of Office of Refugee Resettlement Facilities Request for Information Office of Refugee Resettlement (ORR), Administration for Children and Families (ACF), Department of Health and Human Services (HHS). ACTION: Request for information. AGENCY: The Unaccompanied Children (UC) Program is responsible for the administration of childcare facilities throughout the country that care for unaccompanied children arriving in the United States prior to those children being placed with viable sponsors in the SUMMARY: PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 49549 United States. To inform a strategic and impactful plan for the administration of these facilities HHS is issuing this Request for Information (RFI). The RFI solicits specific input regarding options for a Federal licensure process to ensure continued program operations. DATES: To be considered, public comments must be received electronically no later than October 4, 2021. ADDRESSES: Public comments should be submitted online at https:// www.regulations.gov. All submissions must be submitted to the Docket named ACF–2021–0001 to ‘‘Request for Information (RFI) from Non-Federal Stakeholders: Federal Licensing of ORR Facilities.’’ Comments submitted electronically, including attachments, will be posted to the docket unchanged and available to view by the public. Evidence and information supporting your comment can be submitted as attachments. Please provide your contact information or organization name on the web-based form for possible follow up from HHS. There is a 5,000-character limit on comments and maximum number (10) of attached files and maximum size (10 MB) of each attached file. FOR FURTHER INFORMATION CONTACT: Toby Biswas, Senior Supervisory Policy Counsel, Division of Policy and Procedures, Office of Refugee Resettlement, Administration for Children and Families, Department of Health and Human Services, Washington, DC, (202) 205–4440 or ucpolicy@acf.hhs.gov. SUPPLEMENTARY INFORMATION: ORR facilities are currently administered through a nationwide network of grantee providers that care for unaccompanied children on a day-today basis. These facilities are subject to Federal ORR policies and regulations regarding their operations as well as applicable State-based licensure regulations regarding the operation of childcare facilities in each jurisdiction. The Flores Settlement Agreement (FSA) generally requires that ORR promptly place unaccompanied children into a State licensed child-care program. As of July 2021, ORR operates over 200 licensed care provider facilities in 22 states under approximately 50 separate grants executed under Cooperative Agreements between ORR and the grantee care providers. Each State has its own State licensing standards. The Director of ORR and the Secretary of HHS have broad authority to oversee policies for the care of unaccompanied children, including by identifying a E:\FR\FM\03SEN1.SGM 03SEN1

Agencies

[Federal Register Volume 86, Number 169 (Friday, September 3, 2021)]
[Notices]
[Page 49549]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-19026]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the Advisory Committee on Blood and Tissue Safety and 
Availability

AGENCY: Office of the Assistant Secretary for Health, Office of the 
Secretary, Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The U.S. Department of Health and Human Services is hereby 
giving notice that the Advisory Committee on Blood and Tissue Safety 
and Availability (ACBTSA) will hold a virtual meeting. The meeting will 
be open to the public. The committee will discuss and vote on 
recommendations to improve the supply chain and data infrastructure 
that supports the blood industry, especially during public health 
emergencies. This meeting will build upon the presentations and 
discussions held during the 53rd ACBTSA meeting from August 17-18, 
2021.

DATES: The meeting will take place virtually on Thursday, September 23, 
2021 from approximately 1:00 p.m.-4:00 p.m. Eastern Time (ET). Meeting 
times are tentative and subject to change. The confirmed times and 
agenda items for the meeting will be posted on the ACBTSA web page at 
https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-09-23/ when this information 
becomes available.

FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal 
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS 
Policy, Office of the Assistant Secretary for Health, Department of 
Health and Human Services, Mary E. Switzer Building, 330 C Street SW, 
Suite L600, Washington, DC 20024. Email: [email protected].

SUPPLEMENTARY INFORMATION: ACBTSA is a discretionary Federal advisory 
committee. ACBTSA The Committee is governed by the provisions of the 
Federal Advisory Committee Act (FACA), Public Law 92-463, as amended (5 
U.S.C. app), which sets forth standards for the formation and use of 
advisory committees. On the day of the meeting, please go to https://www.hhs.gov/live/ to view the meeting. The public will have 
an opportunity to present their views to the ACBTSA by submitting a 
written public comment. Comments should be pertinent to the meeting 
discussion. Persons who wish to provide written public comment should 
review instructions at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-09-23/ and 
respond by midnight September 16, 2021, ET. Written public comments 
will be accessible to the public on the ACBTSA web page prior to the 
meeting.
    ACBTSA functions to provide advice to the Secretary through the 
Assistant Secretary for Health on a range of policy issues to include: 
(1) Identification of public health issues through surveillance of 
blood and tissue safety issues with national survey and data tools; (2) 
identification of public health issues that affect availability of 
blood, blood products, and tissues; (3) broad public health, ethical, 
and legal issues related to the safety of blood, blood products, and 
tissues; (4) the impact of various economic factors (e.g., product cost 
and supply) on safety and availability of blood, blood products, and 
tissues; (5) risk communications related to blood transfusion and 
tissue transplantation; and (6) identification of infectious disease 
transmission issues for blood, organs, blood stem cells and tissues. 
The Committee has met regularly since its establishment in 1997.

    Dated: August 27, 2021.
James J. Berger,
Designated Federal Officer, Advisory Committee on Blood and Tissue 
Safety and Availability, Office of Infectious Disease and HIV/AIDS 
Policy.
[FR Doc. 2021-19026 Filed 9-2-21; 8:45 am]
BILLING CODE 4150-28-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.